396 related articles for article (PubMed ID: 15955619)
1. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity.
Swami S; Krishnan AV; Peehl DM; Feldman D
Mol Cell Endocrinol; 2005 Sep; 241(1-2):49-61. PubMed ID: 15955619
[TBL] [Abstract][Full Text] [Related]
2. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
Kim S; Shevde NK; Pike JW
J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
[TBL] [Abstract][Full Text] [Related]
3. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
Ly LH; Zhao XY; Holloway L; Feldman D
Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
[TBL] [Abstract][Full Text] [Related]
4. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
Hedlund TE; Moffatt KA; Miller GJ
Endocrinology; 1996 May; 137(5):1554-61. PubMed ID: 8612485
[TBL] [Abstract][Full Text] [Related]
5. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor.
Dunlop TW; Väisänen S; Frank C; Molnár F; Sinkkonen L; Carlberg C
J Mol Biol; 2005 Jun; 349(2):248-60. PubMed ID: 15890193
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CYP27B1 and CYP24 Increases the Anti-proliferative Effects of 25-Hydroxyvitamin D
Karlsson S; Diaz Cruz MA; Faresjö M; Khamou AP; Larsson D
Anticancer Res; 2021 Oct; 41(10):4733-4740. PubMed ID: 34593422
[TBL] [Abstract][Full Text] [Related]
7. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells.
Farhan H; Wähälä K; Cross HS
J Steroid Biochem Mol Biol; 2003 Mar; 84(4):423-9. PubMed ID: 12732287
[TBL] [Abstract][Full Text] [Related]
8. Co-chaperone potentiation of vitamin D receptor-mediated transactivation: a role for Bcl2-associated athanogene-1 as an intracellular-binding protein for 1,25-dihydroxyvitamin D3.
Chun RF; Gacad M; Nguyen L; Hewison M; Adams JS
J Mol Endocrinol; 2007 Aug; 39(2):81-9. PubMed ID: 17693608
[TBL] [Abstract][Full Text] [Related]
9. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D analogues targeting CYP24 in chronic kidney disease.
Posner GH; Helvig C; Cuerrier D; Collop D; Kharebov A; Ryder K; Epps T; Petkovich M
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):13-9. PubMed ID: 20347976
[TBL] [Abstract][Full Text] [Related]
11. Anti-proliferative activity of 25-hydroxyvitamin D3 in human prostate cells.
Munetsuna E; Kawanami R; Nishikawa M; Ikeda S; Nakabayashi S; Yasuda K; Ohta M; Kamakura M; Ikushiro S; Sakaki T
Mol Cell Endocrinol; 2014 Feb; 382(2):960-70. PubMed ID: 24291609
[TBL] [Abstract][Full Text] [Related]
12. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
13. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells.
Reichrath J; Rech M; Moeini M; Meese E; Tilgen W; Seifert M
Cancer Biol Ther; 2007 Jan; 6(1):48-55. PubMed ID: 17172823
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional inhibition of CYP24 by genistein.
Farhan H; Cross HS
Ann N Y Acad Sci; 2002 Nov; 973():459-62. PubMed ID: 12485911
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
16. Consequences of vitamin D receptor regulation for the 1,25-dihydroxyvitamin D3-induced 24-hydroxylase activity in osteoblast-like cells: initiation of the C24-oxidation pathway.
Staal A; van den Bemd GJ; Birkenhäger JC; Pols HA; van Leeuwen JP
Bone; 1997 Mar; 20(3):237-43. PubMed ID: 9071474
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.
Yee SW; Campbell MJ; Simons C
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):228-35. PubMed ID: 16483768
[TBL] [Abstract][Full Text] [Related]
18. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia.
Zhou C; Assem M; Tay JC; Watkins PB; Blumberg B; Schuetz EG; Thummel KE
J Clin Invest; 2006 Jun; 116(6):1703-12. PubMed ID: 16691293
[TBL] [Abstract][Full Text] [Related]
19. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
Barreto AM; Schwartz GG; Woodruff R; Cramer SD
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
[TBL] [Abstract][Full Text] [Related]
20. A 24-phenylsulfone analog of vitamin D inhibits 1alpha,25-dihydroxyvitamin D(3) degradation in vitamin D metabolism-competent cells.
Lechner D; Manhardt T; Bajna E; Posner GH; Cross HS
J Pharmacol Exp Ther; 2007 Mar; 320(3):1119-26. PubMed ID: 17182978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
